Significance of bioinformatics in research of chronic obstructive pulmonary disease

Journal of Clinical Bioinformatics

Xiangdong Wang¹  Hong Chen² 

[1] Biomedical Research Center, Zhongshan Hospital, Fudan University, Shanghai, China;Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China

关键词: biomarkers;    chronic obstructive pulmonary disease;    proteomics;    genomics;    bioinformatics;   

Others  :  806228
DOI  :  10.1186/2043-9113-1-35

 received in 2010-10-03, accepted in 2011-12-20,  发布年份 2011

【 摘 要 】

Chronic obstructive pulmonary disease (COPD) is an inflammatory disease characterized by the progressive deterioration of pulmonary function and increasing airway obstruction, with high morality all over the world. The advent of high-throughput omics techniques provided an opportunity to gain insights into disease pathogenesis and process which contribute to the heterogeneity, and find target-specific and disease-specific therapies. As an interdispline, bioinformatics supplied vital information on integrative understanding of COPD. This review focused on application of bioinformatics in COPD study, including biomarkers searching and systems biology. We also presented the requirements and challenges in implementing bioinformatics to COPD research and interpreted these results as clinical physicians.

【 授权许可】

   
2011 Chen and Wang; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23(6):932-946.
• [2]Pauwels RA, Rabe KF: Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004, 364(9434):613-620.
• [3]Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al.: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350(26):2645-2653.
• [4]Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al.: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176(6):532-555.
• [5]Lopez AD, Murray CC: The global burden of disease, 1990-2020. Nat Med 1998, 4(11):1241-1243.
• [6]Fang X, Wang X, Bai C: COPD in China: the burden and importance of proper management. Chest 2011, 139(4):920-929.
• [7]Casado B, Iadarola P, Luisetti M, Kussmann M: Proteomics-based diagnosis of chronic obstructive pulmonary disease: the hunt for new markers. Expert Rev Proteomics 2008, 5(5):693-704.
• [8]Chen H, Wang D, Bai C, Wang X: Proteomics-based biomarkers in chronic obstructive pulmonary disease. J Proteome Res 2010, 9(6):2798-2808.
• [9]Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001, 163(5):1256-1276.
• [10]Silverman EK, Spira A, Pare PD: Genetics and genomics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009, 6(6):539-542.
• [11]DeMeo DL, Mariani T, Bhattacharya S, Srisuma S, Lange C, Litonjua A, Bueno R, Pillai SG, Lomas DA, Sparrow D, et al.: Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. Am J Hum Genet 2009, 85(4):493-502.
• [12]Arif E, Vibhuti A, Alam P, Deepak D, Singh B, Athar M, Pasha MA: Association of CYP2E1 and NAT2 gene polymorphisms with chronic obstructive pulmonary disease. Clin Chim Acta 2007, 382(1-2):37-42.
• [13]Vibhuti A, Arif E, Mishra A, Deepak D, Singh B, Rahman I, Mohammad G, Pasha MA: CYP1A1, CYP1A2 and CYBA gene polymorphisms associated with oxidative stress in COPD. Clin Chim Acta 2010, 411(7-8):474-480.
• [14]Zhan P, Wang J, Wei SZ, Qian Q, Qiu LX, Yu LK, Song Y: TNF-308 gene polymorphism is associated with COPD risk among Asians: meta-analysis of data for 6,118 subjects. Mol Biol Rep 2011, 38(1):219-227.
• [15]Gupta J, Bhadoria DP, Lal MK, Kukreti R, Chattopadhaya D, Gupta VK, Dabur R, Yadav V, Chhillar AK, Sharma GL: Association of the PIM3 allele of the alpha-1-antitrypsin gene with chronic obstructive pulmonary disease. Clin Biochem 2005, 38(5):489-491.
• [16]Saxena S, Kumar R, Madan T, Gupta V, Muralidhar K, Sarma PU: Association of polymorphisms in pulmonary surfactant protein A1 and A2 genes with high-altitude pulmonary edema. Chest 2005, 128(3):1611-1619.
• [17]Arif E, Vibhuti A, Deepak D, Singh B, Siddiqui MS, Pasha MA: COX2 and p53 risk-alleles coexist in COPD. Clin Chim Acta 2008, 397(1-2):48-50.
• [18]Butler MW, Fukui T, Salit J, Shaykhiev R, Mezey JG, Hackett NR, Crystal RG: Modulation of Cystatin A Expression in Human Airway Epithelium Related to Genotype, Smoking, COPD, and Lung Cancer. Cancer Res 2011, 71(7):2572-2581.
• [19]Vibhuti A, Arif E, Deepak D, Singh B, Qadar Pasha MA: Genetic polymorphisms of GSTP1 and mEPHX correlate with oxidative stress markers and lung function in COPD. Biochem Biophys Res Commun 2007, 359(1):136-142.
• [20]Sadeghnejad A, Ohar JA, Zheng SL, Sterling DA, Hawkins GA, Meyers DA, Bleecker ER: Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers. Respir Res 2009, 10:21. BioMed Central Full Text
• [21]van Diemen CC, Postma DS, Vonk JM, Bruinenberg M, Schouten JP, Boezen HM: A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am J Respir Crit Care Med 2005, 172(3):329-333.
• [22]Arif E, Ahsan A, Vibhuti A, Rajput C, Deepak D, Athar M, Singh B, Pasha MA: Endothelial nitric oxide synthase gene variants contribute to oxidative stress in COPD. Biochem Biophys Res Commun 2007, 361(1):182-188.
• [23]Sadeghnejad A, Meyers DA, Bottai M, Sterling DA, Bleecker ER, Ohar JA: IL13 promoter polymorphism 1112C/T modulates the adverse effect of tobacco smoking on lung function. Am J Respir Crit Care Med 2007, 176(8):748-752.
• [24]Desai AA, Hysi P, Garcia JG: Integrating genomic and clinical medicine: searching for susceptibility genes in complex lung diseases. Transl Res 2008, 151(4):181-193.
• [25]Patterson SD, Aebersold RH: Proteomics: the first decade and beyond. Nat Genet 2003, 33(Suppl):311-323.
• [26]Marko-Varga G, Fehniger TE: Proteomics and disease--the challenges for technology and discovery. J Proteome Res 2004, 3(2):167-178.
• [27]Lee EJ, In KH, Kim JH, Lee SY, Shin C, Shim JJ, Kang KH, Yoo SH, Kim CH, Kim HK, et al.: Proteomic analysis in lung tissue of smokers and COPD patients. Chest 2009, 135(2):344-352.
• [28]Sepper R, Prikk K: Proteomics: is it an approach to understand the progression of chronic lung disorders? J Proteome Res 2004, 3(2):277-281.
• [29]Ohlmeier S, Vuolanto M, Toljamo T, Vuopala K, Salmenkivi K, Myllarniemi M, Kinnula VL: Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease. J Proteome Res 2008, 7(12):5125-5132.
• [30]Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, Boyd AC, Innes JA, Porteous DJ, Greening AP: Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med 2008, 178(5):444-452.
• [31]Bon JM, Leader JK, Weissfeld JL, Coxson HO, Zheng B, Branch RA, Kondragunta V, Lee JS, Zhang Y, Choi AM, et al.: The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. PLoS One 2009, 4(8):e6865.
• [32]York TP, van den Oord EJ, Langston TB, Edmiston JS, McKinney W, Webb BT, Murrelle EL, Zedler BK, Flora JW: High-resolution mass spectrometry proteomics for the identification of candidate plasma protein biomarkers for chronic obstructive pulmonary disease. Biomarkers 2010, 15(4):367-377.
• [33]Merkel D, Rist W, Seither P, Weith A, Lenter MC: Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics 2005, 5(11):2972-2980.
• [34]Bozinovski S, Hutchinson A, Thompson M, Macgregor L, Black J, Giannakis E, Karlsson AS, Silvestrini R, Smallwood D, Vlahos R, et al.: Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177(3):269-278.
• [35]Bandow JE, Baker JD, Berth M, Painter C, Sepulveda OJ, Clark KA, Kilty I, VanBogelen RA: Improved image analysis workflow for 2-D gels enables large-scale 2-D gel-based proteomics studies--COPD biomarker discovery study. Proteomics 2008, 8(15):3030-3041.
• [36]Nicholson JK, Connelly J, Lindon JC, Holmes E: Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002, 1(2):153-161.
• [37]McClay JL, Adkins DE, Isern NG, O'Connell TM, Wooten JB, Zedler BK, Dasika MS, Webb BT, Webb-Robertson BJ, Pounds JG, et al.: (1)H nuclear magnetic resonance metabolomics analysis identifies novel urinary biomarkers for lung function. J Proteome Res 2010, 9(6):3083-3090.
• [38]de Laurentiis G, Paris D, Melck D, Maniscalco M, Marsico S, Corso G, Motta A, Sofia M: Metabonomic analysis of exhaled breath condensate in adults by nuclear magnetic resonance spectroscopy. Eur Respir J 2008, 32(5):1175-1183.
• [39]Trune DR, Larrain BE, Hausman FA, Kempton JB, Macarthur CJ: Simultaneous measurement of multiple ear proteins with multiplex ELISA assays. Hear Res 2010.
• [40]Elshal MF, McCoy JP: Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 2006, 38(4):317-323.
• [41]Ray CA, Bowsher RR, Smith WC, Devanarayan V, Willey MB, Brandt JT, Dean RA: Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum. J Pharm Biomed Anal 2005, 36(5):1037-1044.
• [42]Farlow EC, Patel K, Basu S, Lee BS, Kim AW, Coon JS, Faber LP, Bonomi P, Liptay MJ, Borgia JA: Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res 2010, 16(13):3452-3462.
• [43]Bhattacharya S, Srisuma S, Demeo DL, Shapiro SD, Bueno R, Silverman EK, Reilly JJ, Mariani TJ: Molecular biomarkers for quantitative and discrete COPD phenotypes. Am J Respir Cell Mol Biol 2009, 40(3):359-367.
• [44]Agusti A, Sobradillo P, Celli B: Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Am J Respir Crit Care Med 2011, 183(9):1129-1137.
• [45]Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ: An integrative systems biology approach to understanding pulmonary diseases. Chest 2010, 137(6):1410-1416.
• [46]Comandini A, Marzano V, Curradi G, Federici G, Urbani A, Saltini C: Markers of anti-oxidant response in tobacco smoke exposed subjects: a data-mining review. Pulm Pharmacol Ther 2010, 23(6):482-492.
• [47]Maier D, Kalus W, Wolff M, Kalko SG, Roca J, Marin de Mas I, Turan N, Cascante M, Falciani F, Hernandez M, et al.: Knowledge management for systems biology a general and visually driven framework applied to translational medicine. BMC Syst Biol 2011, 5:38. BioMed Central Full Text
• [48]Paoletti M, Camiciottoli G, Meoni E, Bigazzi F, Cestelli L, Pistolesi M, Marchesi C: Explorative data analysis techniques and unsupervised clustering methods to support clinical assessment of Chronic Obstructive Pulmonary Disease (COPD) phenotypes. J Biomed Inform 2009, 42(6):1013-1021.
• [49]Studer SM, Kaminski N: Towards systems biology of human pulmonary fibrosis. Proc Am Thorac Soc 2007, 4(1):85-91.
• [50]Kauffmann F: Post-genome respiratory epidemiology: a multidisciplinary challenge. Eur Respir J 2004, 24(3):471-480.
• [51]Wang X, Adler KB, Chaudry IH, Ward PA: Better understanding of organ dysfunction requires proteomic involvement. J Proteome Res 2006, 5(5):1060-1062.
• [52]Plymoth A, Yang Z, Lofdahl CG, Ekberg-Jansson A, Dahlback M, Fehniger TE, Marko-Varga G, Hancock WS: Rapid proteome analysis of bronchoalveolar lavage samples of lifelong smokers and never-smokers by micro-scale liquid chromatography and mass spectrometry. Clin Chem 2006, 52(4):671-679.
• [53]Reisdorph NA, Reisdorph R, Bowler R, Broccardo C: Proteomics methods and applications for the practicing clinician. Ann Allergy Asthma Immunol 2009, 102(6):523-529.
• [54]Lin JL, Bonnichsen MH, Nogeh EU, Raftery MJ, Thomas PS: Proteomics in detection and monitoring of asthma and smoking-related lung diseases. Expert Rev Proteomics 2010, 7(3):361-372.